Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $73.74 million versus the consensus estimate of $71.5 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.